Trust celebrates ranking second for ovarian cancer survival rates

Somerset has ranked second in England for ovarian cancer survival rates, according to an NHS England report.

(c) Somerset NHS Foundation Trust

(c) Somerset NHS Foundation Trust

The latest National Ovarian Cancer Audit taken in 2021 shows 77% of those with ovarian cancer are surviving at least one year after their diagnosis in the county, with only Barts Health NHS Trust ranking higher.

Jo Morrison, a gynaecological-oncology consultant at Somerset NHS Foundation Trust, said: ‘To come second in the country for ovarian cancer survival rates is an incredible achievement. Our 12-month survival rates are similar to those in the best-performing countries internationally, such as Norway and Denmark.'

The National Ovarian Cancer Audit was launched following concerns cancer survival rates in the UK weren't as good as in other countries in Europe.

Barts finished in first place for one-year survival rates in the audit and topped five-year survival rates in 2023.

The work was originally driven by clinicians and patient support groups who wanted to improve outcomes through understanding of why there was so much variation across the country.

Morrison added: ‘Thanks to the support of the British Gynaecological Cancer Society and the ovarian cancer charities, we contributed to a national pilot audit, which demonstrated big differences between centres across the UK.

‘This national audit has now been adopted by the NHS, through the National Cancer Audit Collaborating Centre, so it will continue long-term.'

BREAKING NEWS: Five-year settlement rights given to health and care workers

BREAKING NEWS: Five-year settlement rights given to health and care workers

By Lee Peart 02 November 2026

Care workers earning £25,000 and doctors and nurses will be given settlement rights after five years under reforms announced by the home secretary.

Trial aims to safely cut breast cancer radiotherapy treatment time

By Lee Peart 02 November 2026

Thirty-nine hospitals have joined a trial to test whether breast cancer radiotherapy can be safely cut from three weeks to 5 days.

Automation isn't just about efficiency; it's how the NHS will retain its people

26 October 2026

By Chris Sleight, former chief officer of the Greater Manchester Diagnostic Network and strategic director for diagnostics at Digital Workforce


Popular articles by Lee Peart